DiamiR Biosciences Secures EU Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Differential Diagnosis of Amyotrophic Lateral Sclerosis NEW HAVEN, CT, and MONMOUTH JUNCTION, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that...

DiamiR Announces Oral Presentation at Biomarkers Summit 2016 MONMOUTH JUNCTION, NJ--(Marketwired - March 18, 2016) -  DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that...

DiamiR Announces Research Collaboration With Johnson & Johnson Innovation MONMOUTH JUNCTION, NJ--(Marketwired - January 11, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research...

DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...